Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update November 2022

Rothschedl, E. and Wolf, S. (2022): Relugolix (Orgovyx®) for the treatment of advanced hormone-sensitive prostate cancer. Update November 2022. Oncology Fact Sheet Nr. 80.

[thumbnail of Oncology Fact Sheet Nr.80_2nd Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
95kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WJ Urogenital system > WJ 700-875 Male genitalia
Language:	English
Series Name:	Oncology Fact Sheet Nr. 80
Deposited on:	28 Mar 2022 12:35
Last Modified:	22 Nov 2022 18:09

Repository Staff Only: item control page